Read by QxMD icon Read

Myeloma multiple 2016

Elisabet E Manasanch, Jatin J Shah, Hans C Lee, Donna M Weber, Sheeba K Thomas, Behrang Amini, Lei Feng, Zuzana Berkova, Michelle Hildebrandt, Robert Z Orlowski
BACKGROUND: Bortezomib with lenalidomide and dexamethasone (VRd) is a standard regimen for the front-line treatment of multiple myeloma. Panobinostat is approved in combination with bortezomib and dexamethasone in patients with myeloma who 'have been given at least two previous regimens including bortezomib and an immunomodulatory agent. We aimed to determine the maximum tolerated dose of a new regimen combining VRd with panobinostat in patients with newly diagnosed multiple myeloma. METHODS: In this phase 1 study, we enrolled patients from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) with newly diagnosed multiple myeloma who were aged 18 years or older and eligible for autologous stem-cell transplant (ASCT) according to International Myeloma Working Group 2014 diagnostic criteria...
December 2018: Lancet Haematology
Mélanie Tia Weu, Cyr Guei Monlet, Amidou Sawadogo, Albert Coulibaly Pessa, Amelie Lagou Delphine, Apollinaire Gnionsahé Daze
BACKGROUND: Renal involvement is common during monoclonal gammopathies and their occurrence impacts the survival of the patients. Our objective was to describe the renal features during monoclonal gammopathies from 2004 to 2016 at the University Hospital of Yopougon in Abidjan. METHODS: Renal failure was defined as blood creatinine level > 20 mg/L and/or proteinuria > 500 mg/24 hours. RESULTS: We identified 42 cases of monoclonal gammopathiesincluding multiple myeloma (n=40) and monoclonal gammopathy of underdetermined significance (n=2)...
2018: Le Mali Médical
Nisha S Joseph, Jonathan L Kaufman, Lawrence H Boise, Kelly Valla, Dhwani K Almaula, Chikaodili O Obidike, Amelia A Langston, Edmund K Waller, Hanna J Khoury, Christopher R Flowers, Michael Graiser, Leonard T Heffner, Sagar Lonial, Ajay K Nooka
High-dose therapy (HDT) and autologous stem cell transplantation (ASCT) are established components in the treatment of multiple myeloma; however, undergoing transplantation usually requires hematopoietic support, which poses a challenge among patients who are unwilling to receive blood products. Most transplant centers decline HDT/ASCT to these patients because of safety concerns. Here, the authors' institutional data on safety, engraftment parameters, and survival outcomes after bloodless ASCT (BL-ASCT) are examined among patients with myeloma...
November 27, 2018: Cancer
Praful Ravi, Shaji K Kumar, Lindsey Roeker, Wilson Gonsalves, Francis Buadi, Martha Q Lacy, Ronald S Go, Angela Dispenzieri, Prashant Kapoor, John A Lust, David Dingli, Yi Lin, Stephen J Russell, Nelson Leung, Morie A Gertz, Robert A Kyle, P Leif Bergsagel, S Vincent Rajkumar
The current definition of plasma cell leukemia (PCL)- ≥ 20% circulating plasma cells (CPCs) on peripheral smear and plasma cell count ≥ 2 × 109 /L-may be too stringent. We reviewed outcomes of 176 multiple myeloma (MM) patients diagnosed between 1971 and 2016, and who had CPCs detectable at diagnosis, to determine whether a lower threshold could be used to diagnose PCL. Median overall survival (mOS) was 1.1 years (95% CI 0.8-1.4) and was similar between patients with < 5% (n = 54, mOS = 1...
November 15, 2018: Blood Cancer Journal
Carolyne Croizier, Sébastien Bailly
Daratumumab is a monoclonal antibody that targets CD38. It has an anti-tumor action on the myeloma cell and an immunomodulatory action. For relapsing and/or refractory myeloma patients, daratumumab is effective both alone and in combination and significantly improves progression-free survival. Daratumumab has been approved in 2016 in France for treatment of relapses or refractory multiple myeloma.
November 2018: Bulletin du Cancer
Andrea Angelini, Giulia Trovarelli, Antonio Berizzi, Elisa Pala, Anna Breda, Marco Maraldi, Pietro Ruggieri
BACKGROUND: Metastatic lesions to the proximal femur occur frequently and require special consideration due to the high risk of pathologic fractures. Type of surgery might influence patient survival considering the growing concept of oligometastases. In fact, the use of modular tumor megaprosthesis is increasing in the last decades compared to intramedullary nailing. Aim of this study was to evaluate oncological and functional results of treatment in patients with pathologic or impending fracture of the proximal femur, with patient survival being the primary, complications the secondary, and functional results the tertiary endpoint...
November 2018: Injury
Gabriel Rinnerthaler, Simon Peter Gampenrieder, Andreas Petzer, Sonja Burgstaller, David Fuchs, Dieter Rossmann, Marija Balic, Daniel Egle, Holger Rumpold, Christian F Singer, Rupert Bartsch, Edgar Petru, Thomas Melchardt, Hanno Ulmer, Brigitte Mlineritsch, Richard Greil
BACKGROUND: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with poor prognosis. Up to now, no targeted treatment beyond anti-VEGF therapy has been approved for TNBC and cytotoxic agents remain the mainstay of treatment. Ixazomib is a selective and reversible inhibitor of the proteasome, which has been mainly investigated in the treatment of multiple myeloma. In a preclinical study TNBC cells were treated with the first-generation proteasome inhibitor bortezomib in combination with cisplatin and synergistic efficacy was demonstrated...
November 6, 2018: BMC Cancer
Carolina Marini, Tânia Maia, Rui Bergantim, Jorge Pires, Eliana Aguiar, José Eduardo Guimarães, Fernanda Trigo
Autologous stem cell transplantation (ASCT) is still debatable in treatment of patients over 65 years with multiple myeloma (MM). We performed a retrospective analysis of newly diagnosed MM patients who underwent ASCT between January 2010 and July 2016. A non-transplanted group with similar clinical characteristics, aged 65-70 years old, diagnosed and treated in the same timeline was used for comparison. We analyzed a total of 155 patients, 132 of which underwent ASCT (≤ 65 years, n = 103, median 56 years; > 65 years, n = 29, median 67 years) and 23 non-transplanted (median 68 years)...
October 27, 2018: Annals of Hematology
Jinhuan Xu, Qiuxiang Wang, Hao Xu, Chaojiang Gu, Lijun Jiang, Jue Wang, Di Wang, Bin Xu, Xia Mao, Jin Wang, Zhiqiong Wang, Yi Xiao, Yicheng Zhang, Chunrui Li, Jianfeng Zhou
BACKGROUND: POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome still has no standard treatment. On the basis that both POEMS syndrome and myeloma have an underlying plasma cell dyscrasia, anti-myeloma therapy can be expected to be useful for POEMS syndrome. Chimeric antigen receptor T (CAR-T) cells targeting B cell maturation antigen (BCMA) has been used in the treatment of relapsed and refractory multiple myeloma (RRMM). No POEMS syndrome cases treated with anti-BCMA CAR-T cells have been reported...
October 22, 2018: Journal of Hematology & Oncology
Marlies Antlanger, Tobias Dust, Thomas Reiter, Alexandra Böhm, Wolfgang W Lamm, Max Gornicec, Ella Willenbacher, David Nachbaur, Roman Weger, Werner Rabitsch, Susanne Rasoul-Rockenschaub, Nina Worel, Daniel Lechner, Hildegard Greinix, Felix Keil, Heinz Gisslinger, Hermine Agis, Maria-Theresa Krauth
BACKGROUND: Renal impairment (RI) is a negative prognostic factor in Multiple Myeloma (MM) and affected patients are often excluded from autologous stem cell transplantation (ASCT). However, it remains unclear whether historically inferior outcome data still hold true. METHODS: From a total of 475 eligible MM patients who had undergone ASCT between 1998 and 2016, 374 were included in this multi-centric retrospective cohort study. Renal function was determined both at the time of MM diagnosis and ASCT by estimated glomerular filtration rate (eGFR according to the MDRD formula, RI defined as eGFR < 60 ml/min/1...
October 20, 2018: BMC Cancer
Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, Morie A Gertz, Francis K Buadi, Martha Q Lacy, David Dingli, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs, Wilson I Gonsalves, Rahma M Warsame, Taxiarchis Kourelis, Yi Lisa Hwa, Prashant Kapoor, Robert A Kyle, Nelson Leung, Ronald S Go, S Vincent Rajkumar, Shaji K Kumar
Achieving a complete response (CR) is associated with improved overall survival (OS) in multiple myeloma (MM), but data on duration of CR (DurCR) are limited. We evaluated 351 patients (2004-2016), achieving CR with first-line therapy. Patients with sustained DurCR ≥ 24 months (n = 177) had better OS; 150 vs. 81 months, p < 0.001. DurCR ≥ 24 months remained a significant predictor for OS (HR: 0.3, 95% CI: 0.2-0.5, p < 0.001) after adjusting for age, revised ISS stage, transplant and maintenance therapy...
October 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Hai-Min Chen, Wei Wei, Rong Peng, Hao-Tian Shi, Xiao-Ling Chen, Fan Zhou
OBJECTIVE: To investigate the prognostic value of karyotypic abnormalities in evaluation of prognosis of patients with multiple myeloma. METHODS: The clinical and laboratory data of patients with newly diagnosed multiple myeloma (NDMM) were retrospectively analyzed in our hospital from May 2010 to May 2016. Patients who carried t(4; 14), t(14; 16) or 17P- (at least one of them) were defined as the patients with high-risk karyotype, whereas patients characterized by the absence of the above-mentioned abnormalities were defined as patients with standard-risk karyotype...
October 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
Chao-Yu Wang, Bing Xia, Qiao-Yang Ning, Chen Tian, Hai-Feng Zhao, Hong-Liang Yang, Meng-Zhen Li, Zhi-Gang Zhao, Xiao-Fang Wang, Ya-Fei Wang, Yong Yu, Yi-Zhuo Zhang
OBJECTIVE: To evaluate the therapeutic efficacy and prognosis of autologous stem Hematopoietic cell transplantation (auto-HSCT) in multiple myeloma (MM) patients. METHODS: A retrospective study was conducted for 56 patients diagnosed with MM and then received auto-HSCT in our hospital from December 2008 to September 2016. RESULTS: All the patients successfully underwent hematopoietic reconstruction without transplantation-related mortality (TRM)...
October 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
Nicolas Despiégel, Chantal Touboul, Alain Flinois, Grèce Saba, Florence Suzan, Sebastian Gonzalez-McQuire, Franck Bonnetain
INTRODUCTION: New therapies for multiple myeloma (MM) have improved life expectancy, but health-related quality of life (HRQoL) data from patients with MM in the real-world setting are lacking. This study, conducted in France, explored the associations between treatment outcomes and HRQoL in patients with MM. PATIENTS AND METHODS: This observational, cross-sectional, multicenter study enrolled patients (≥ 18 years old) with symptomatic MM who had consulted a physician at least once between February and March 2016...
September 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
Benjamin A Derman, Jochen Reiser, Sanjib Basu, Agne Paner
Introduction: Renal insufficiency (RI) in Multiple Myeloma (MM) portends a higher tumor burden and worse prognosis. Reversal of RI in newly diagnosed MM (NDMM) improves patient outcomes, but it is unknown if there is a disparity in renal recovery in NDMM between African Americans (AA) and non-African Americans. Methods: A retrospective chart review was conducted of 690 patients with NDMM at Rush University Medical Center from 2005 to 2016. 118 patients (59 AA and 59 non-AA) with NDMM and an estimated glomerular filtration rate (eGFR) < 90 mL/min/1...
2018: International Journal of Nephrology
Firoozeh Sahebi, Laurent Garderet, Abraham S Kanate, Diderik-Jan Eikema, Nina Simone Knelange, Omar F Dávila Alvelo, Yener Koc, Didier Blaise, Qaiser Bashir, José M Moraleda, Peter Dreger, James F Sanchez, Stefan Ciurea, Harry Schouten, Nirav N Shah, Mareike Verbeek, Wolf Rösler, Jose L Diez-Martin, Stefan Schoenland, Anita D'Souza, Nicolaus Kröger, Parameswaran Hari
Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors has the potential for long-term disease control in a subset of high-risk patients with multiple myeloma (MM); however, the data on using haploidentical donors in this disease are limited. We conducted a retrospective analysis to examine the outcomes of patients with MM who underwent haploidentical allo-HCT within European Society for Blood and Marrow Transplantation/Center for International Blood and Marrow Transplant Research centers...
September 20, 2018: Biology of Blood and Marrow Transplantation
Maria Chaudhry, Raphael Steiner, Catherine Claussen, Krina Patel, Hans Lee, Donna Weber, Sheeba Thomas, Chun Feng, Behrang Amini, Robert Orlowski, Lei Feng, Elisabet E Manasanch
Multiple myeloma (MM) and Waldenström's macroglobulinemia (WM) are plasma cell disorders often treated with proteasome inhibitors. Recently, several studies evaluated carfilzomib as an initial treatment for these diseases and reported outstanding clinical outcomes. We conducted a retrospective study to report the efficacy and safety of frontline carfilzomib-based combinations in a standard of care setting. From 2014 until 2016 we identified newly diagnosed MM (n = 54) and WM (n = 6) patients treated with carfilzomib as initial therapy who met study inclusion criteria...
September 19, 2018: Leukemia & Lymphoma
S W Yang, R J Ma, J J Zhao, X L Yuan, L Jiang, J Yang, P C Lei, Y Zhang, L Zhang, G Liu, F Wang, Z M Zhu
Objective: To explore the clinical significance of serum bone metabolites β C-termianl telopeptide of type Ⅰ collagen(β-CTX), Procollagen type Ⅰ N-terminal peptide(PINP) concentration and ratio of beta -CTX/PINP in multiple myeloma bone disease (MMBD) and bone metastases. Methods: A total of 31 cases of MM, 46 cases of bone metastases and 12 healthy controls were enrolled in the department of hematology, oncology and physical examination center of Henan Provincial People's Hospital respectively from October 2016 to October 2017...
August 28, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Nur Soyer, Püsem Patır, Ayşe Uysal, Mustafa Duran, Hatice Demet Ünal, Raika Durusoy, Murat Tombuloğlu, Fahri Şahin, Mahmut Töbü, Filiz Vural, Güray Saydam
Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016. Materials and methods: Patients’ records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed. Results: One hundred and twenty patients (71 males; 59...
August 16, 2018: Turkish Journal of Medical Sciences
Martin Bommer, Miriam Kull, Veronica Teleanu, Phyllis Schwarzwälder, Manuela Feuring-Buske, Jan Kroenke, Donald Bunjes, Christian Langer
INTRODUCTION: Involvement of the central nervous system in patients with multiple myeloma is a rare event. We evaluated the diagnostic workup and prognosis of patients with leptomeningeal myelomatosis (LMM). METHODS: Between April 2005 and April 2016, we identified 16 cases with LMM. The involvement was diagnosed by magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) cytology as well as flow cytometry. Fluorescence in situ hybridization (FISH) was used in 8/16 cases...
2018: Acta Haematologica
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"